DFO
SPRY icon

Duquesne Family Office’s ARS Pharmaceuticals SPRY Stock Holding History

Duquesne Family Office’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-536,900
Closed -$7.79M – 96
2024
Q3 		$7.79M Buy
+536,900
New +$6.39M 0.26% 56

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Duquesne Family Office's SPRY Position: Q4 2024 in Review

Duquesne Family Office sold out of ARS Pharmaceuticals (SPRY) in Q4 2024, closing a stake of 536,900 shares — an estimated $7.79M sold.

Duquesne Family Office first reported a position in SPRY in Q3 2024 and held it in 1 quarter. The position peaked at $7.79M in Q3 2024. 165 funds tracked by Wall St. Rank hold SPRY as of Q4 2024.

  • Duquesne Family Office reported no remaining ARS Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Duquesne Family Office sold 536,900 ARS Pharmaceuticals shares in Q4 2024, an estimated $7.79M.
  • Duquesne Family Office first reported a position in ARS Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Duquesne Family Office's ARS Pharmaceuticals position peaked at $7.79M in Q3 2024.
  • 165 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q4 2024.

Based on Duquesne Family Office's 13F filing for Q4 2024, filed 14 Feb 2025.